FY2028 EPS Estimates for Nuvectis Pharma, Inc. (NASDAQ:NVCT) Boosted by Roth Capital

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Research analysts at Roth Capital increased their FY2028 earnings estimates for Nuvectis Pharma in a research report issued to clients and investors on Tuesday, May 7th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings of $3.90 per share for the year, up from their prior estimate of $3.59. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.52) per share.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01).

Separately, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Nuvectis Pharma in a research report on Wednesday.

Nuvectis Pharma Stock Down 10.6 %

Shares of Nuvectis Pharma stock opened at $6.43 on Thursday. Nuvectis Pharma has a 52-week low of $5.92 and a 52-week high of $18.65. The company has a 50 day moving average of $8.17 and a 200 day moving average of $8.21. The company has a market capitalization of $118.13 million, a P/E ratio of -4.50 and a beta of 0.45.

Institutional Investors Weigh In On Nuvectis Pharma

Several large investors have recently modified their holdings of NVCT. Baldwin Brothers LLC MA raised its position in Nuvectis Pharma by 22.0% in the 4th quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company’s stock valued at $1,185,000 after purchasing an additional 25,660 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Nuvectis Pharma in the fourth quarter valued at about $160,000. Blue Zone Wealth Advisors LLC purchased a new position in shares of Nuvectis Pharma during the first quarter worth about $118,000. Finally, Strs Ohio increased its position in Nuvectis Pharma by 178.6% in the 3rd quarter. Strs Ohio now owns 3,900 shares of the company’s stock valued at $50,000 after acquiring an additional 2,500 shares during the period. 96.77% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Ron Bentsur acquired 5,000 shares of Nuvectis Pharma stock in a transaction dated Monday, March 18th. The stock was acquired at an average price of $10.29 per share, for a total transaction of $51,450.00. Following the transaction, the chief executive officer now owns 3,242,484 shares of the company’s stock, valued at $33,365,160.36. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 38.85% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.